Stockscreener 앱 받기
0.284
4.70%
-0.014
시간 외 거래:
.28
-0.004
-1.41%
전일 마감가:
$0.298
열려 있는:
$0.306
하루 거래량:
8.87M
Relative Volume:
5.11
시가총액:
$2.87M
수익:
-
순이익/손실:
$-8.26M
주가수익비율:
-0.0053
EPS:
-53.609
순현금흐름:
$-12.17M
1주 성능:
+15.07%
1개월 성능:
-78.96%
6개월 성능:
-82.79%
1년 성능:
-97.73%
1일 변동 폭
$0.268
$0.3396
1주일 범위
$0.2315
$0.3396
52주 변동 폭
$0.2177
$13.09
Gri Bio Inc Stock (GRI) Company Profile
명칭
Gri Bio Inc
전화
(619) 400-1171
주소
2223 AVENIDA DE LA PLAYA, LA JOLLA
GRI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GRI
Gri Bio Inc
|
0.284 | 3.02M | 0 | -8.26M | -12.17M | -53.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Gri Bio Inc Stock (GRI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-09 | 개시 | H.C. Wainwright | Buy |
Gri Bio Inc 주식(GRI)의 최신 뉴스
Is GRI Bio Inc. stock affected by interest rate hikesWall Street Watch & Safe Entry Trade Signal Reports - ulpravda.ru
GRI Bio stock rises on positive Phase 2a immune data for IPF treatment - Investing.com
GRI Bio reports positive Phase 2a data for IPF treatment By Investing.com - Investing.com India
GRI Bio, Inc. Announces Positive Phase 2a Trial Data for GRI-0621 - TradingView — Track All Markets
Experimental drug shows signs of reversing lung scarring in IPF study - Stock Titan
What Wall Street predicts for GRI Bio Inc. stock priceBullish Engulfing Patterns & Small Entry Portfolio - ulpravda.ru
What technical signals suggest for GRI Bio Inc. stock2026 world cup usa national team third place match goalkeepers high defensive line group prediction insights - ulpravda.ru
What drives GRI Bio Inc stock priceEarnings Forecast Updates & High Yield Trading Growth - earlytimes.in
Decliners Report: Is GRI Bio Inc stock attractive for hedge funds2025 Bull vs Bear & Free Community Consensus Stock Picks - moha.gov.vn
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
GRI Bio approves reverse stock split, stockholders vote in favor - MSN
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
GRI Bio Inc. (GRI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What insider trading reveals about GRI Bio Inc. stockLong Setup & Real-Time Buy Zone Alerts - Улправда
Why GRI Bio Inc. stock remains on buy listsWeekly Trade Analysis & Weekly Setup with High ROI Potential - Улправда
Why GRI Bio Inc. stock could be next big winnerJuly 2025 Intraday Action & Expert Approved Momentum Ideas - DonanımHaber
What sentiment indicators say about GRI Bio Inc. stockWeekly Market Outlook & Weekly Momentum Stock Picks - Улправда
Oral therapy GRI-0621 boosts lung function, repairs tissue in IPF: Data - Pulmonary Fibrosis News
GRI Bio announces GRI-0621-IPF-02 trial met primary, secondary endpoints - MSN
GRI Bio Closes $8 Million Public Offering - The Globe and Mail
GRI Bio closes $8 million public offering of common stock and warrants - Investing.com Nigeria
GRI Bio closes $8 million public offering of common stock and warrants By Investing.com - Investing.com South Africa
GRI Bio (Nasdaq: GRI) details closing of offering, equity over $2.5M post-transaction - Stock Titan
GRI Bio Announces Closing of $8.0 Million Public Offering - GlobeNewswire
GRI Bio Launches $6.7 Million Public Offering - TipRanks
GRI Bio (NASDAQ: GRI) details $6.7M equity deal and runway into Q4 2026 - Stock Titan
GRI Bio prices $8 million public offering at $0.75 per share - Investing.com
GRI Bio announces pricing of $8M public offering - MSN
GRI Bio’s IPF drug shows positive Phase 2a results with improved lung function - Investing.com India
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
GRI Bio Announces Pricing of $8,000,000 Million Public Offering - The Manila Times
GRI Bio (NASDAQ: GRI) prices $8,000,000 offering of 10,666,667 shares at $0.75 - Stock Titan
What's Going On With GRI Bio Stock Thursday?GRI Bio (NASDAQ:GRI) - Benzinga
GRI Bio’s tazarotene achieves Phase IIa IPF success - Yahoo
GRI Bio Meets Key Goals In Phase 2 Trial Of GRI-0621 For Idiopathic Pulmonary Fibrosis - Nasdaq
GRI Bio announces positive Phase 2a trial results - MSN
GRI Bio Announces Positive Phase 2a Trial Results - TipRanks
GRI Bio, Inc. Announces Positive Phase 2a Trial Results for GRI-0621 - TradingView
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewswire
A new trading data show Milestone Pharmaceuticals Inc (MIST) is showing positive returns. - Setenews
GRI Bio (NASDAQ: GRI) updates Form S-1 with extensive warrant and contract exhibits - Stock Titan
Financial Contrast: CalciMedica (NASDAQ:CALC) and GRI Bio (NASDAQ:GRI) - Defense World
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.45% - Investing.com UK
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.45% - Investing.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
GRI Bio Reports Positive Phase 2a Trial Results - TipRanks
GRI Bio Increceives topline data from phase 2a trial for idiopathic pulmonary fibrosisSEC filing - marketscreener.com
GRI Bio Reports Positive Phase 2a Trial Results for IPF Treatment - TradingView
GRI Bio (NASDAQ: GRI) reports Phase 2a IPF topline results for GRI-0621 - Stock Titan
Ascendiant Capital Maintains GRI Bio (GRI) Buy Recommendation - Nasdaq
Ascendiant Capital Raises Price Target for GRI to $36.00 | GRI S - GuruFocus
Gri Bio Inc (GRI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.80%
4.56%
자본화:
|
볼륨(24시간):